News List
Gilead's Veklury has been approved：Veklury is the First Approved Treatment Option for COVID-19 in the European Union
2020-07-06
At present,The COVID-19 epidemic continues to spread rapidly around the world. As of 01am, July 04, 2020, there have bee
Announcement on the extension of CPHI North America 2020 in September
2020-06-19
Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North American Exhibition hel
New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
2020-06-17
Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new drug for insomnia, i
The first c-Met inhibitor approved by the FDA to market
2020-05-18
On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patients with locally adva
The cortisol synthesis inhibitor Isturia developed by Recordati has been approved by the European Union!
2020-04-10
On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the European Commission (EC) h
Fapilavir completes clinical research and shows good clinical efficacy
2020-03-23
On March 17th, the State Council's joint prevention and control mechanism held a press conference on the latest rese
Migraine relieved within 1 hour, FDA approves new oral medication
2020-03-01
2020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibitor Nurtec (rimegepant
Insomnia and schizophrenia innovative treatments approved
2020-02-04
Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide secreted by the hypo
First oral small molecule CGRP receptor inhibitor approved today for the treatment of migraine
2020-01-10
Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related peptide (CGRP) receptor a
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
2019-12-21
Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22studies that explore